Literature DB >> 14653830

Antibiotic treatment of small bowel bacterial overgrowth in patients with Crohn's disease.

F Castiglione1, A Rispo, E Di Girolamo, A Cozzolino, F Manguso, R Grassia, G Mazzacca.   

Abstract

BACKGROUND: Small bowel bacterial overgrowth is common in Crohn's disease but its treatment is not clearly defined. Metronidazole and ciprofloxacin are effective antibiotics in active Crohn's disease. AIM: To investigate the efficacy of metronidazole and ciprofloxacin in the treatment of bacterial overgrowth in patients with Crohn's disease. PATIENTS AND METHODS: We performed the lactulose breath test in 145 consecutive patients affected by Crohn's disease. Patients positive to the lactulose breath test underwent a glucose breath test to confirm the overgrowth. These patients were randomized in two treatment groups: metronidazole 250 mg t.d.s. (Group A) and ciprofloxacin 500 mg b.d. (Group B), both orally for 10 days. The glucose breath test was repeated at the end of treatment. The clinical outcome after therapy was also recorded.
RESULTS: Bacterial overgrowth was present in 29 patients (20%). Breath test normalization occurred in 13 out of 15 patients treated by metronidazole and in all 14 patients treated by ciprofloxacin (P = ns). In both groups antibiotic treatment induced an improvement of intestinal symptoms: bloating (Group A 85% and Group B 83%), stool softness (44% and 50%), and abdominal pain (50% and 43%).
CONCLUSIONS: Small bowel bacterial overgrowth is a frequent condition in Crohn's disease which can be effectively treated by metronidazole or ciprofloxacin.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14653830     DOI: 10.1046/j.1365-2036.2003.01800.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  26 in total

Review 1.  Meta-analysis: antibiotic therapy for small intestinal bacterial overgrowth.

Authors:  S C Shah; L W Day; M Somsouk; J L Sewell
Journal:  Aliment Pharmacol Ther       Date:  2013-09-04       Impact factor: 8.171

Review 2.  Microbiota: a novel regulator of pain.

Authors:  Manon Defaye; Sandie Gervason; Christophe Altier; Jean-Yves Berthon; Denis Ardid; Edith Filaire; Frédéric Antonio Carvalho
Journal:  J Neural Transm (Vienna)       Date:  2019-09-24       Impact factor: 3.575

Review 3.  British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults.

Authors:  Christopher Andrew Lamb; Nicholas A Kennedy; Tim Raine; Philip Anthony Hendy; Philip J Smith; Jimmy K Limdi; Bu'Hussain Hayee; Miranda C E Lomer; Gareth C Parkes; Christian Selinger; Kevin J Barrett; R Justin Davies; Cathy Bennett; Stuart Gittens; Malcolm G Dunlop; Omar Faiz; Aileen Fraser; Vikki Garrick; Paul D Johnston; Miles Parkes; Jeremy Sanderson; Helen Terry; Daniel R Gaya; Tariq H Iqbal; Stuart A Taylor; Melissa Smith; Matthew Brookes; Richard Hansen; A Barney Hawthorne
Journal:  Gut       Date:  2019-09-27       Impact factor: 23.059

Review 4.  Small Intestinal Bacterial Overgrowth in Patients With Cirrhosis.

Authors:  Gaurav Ghosh; Arun B Jesudian
Journal:  J Clin Exp Hepatol       Date:  2018-08-27

Review 5.  Small intestinal bacterial overgrowth syndrome.

Authors:  Jan Bures; Jiri Cyrany; Darina Kohoutova; Miroslav Förstl; Stanislav Rejchrt; Jaroslav Kvetina; Viktor Vorisek; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-06-28       Impact factor: 5.742

6.  Small intestinal bacterial overgrowth: a comprehensive review.

Authors:  Andrew C Dukowicz; Brian E Lacy; Gary M Levine
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-02

7.  Effectiveness of Saccharomyces boulardii and Metronidazole for Small Intestinal Bacterial Overgrowth in Systemic Sclerosis.

Authors:  Grettel García-Collinot; Eduardo Osiris Madrigal-Santillán; Michel A Martínez-Bencomo; Rosa A Carranza-Muleiro; Luis J Jara; Olga Vera-Lastra; Daniel H Montes-Cortes; Gabriela Medina; María Pilar Cruz-Domínguez
Journal:  Dig Dis Sci       Date:  2019-09-23       Impact factor: 3.199

8.  Small intestine bacterial overgrowth and irritable bowel syndrome-related symptoms: experience with Rifaximin.

Authors:  Sergio Peralta; Claudia Cottone; Tiziana Doveri; Piero Luigi Almasio; Antonio Craxi
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

9.  Anti-microbial antibodies in celiac disease: trick or treat?

Authors:  Maria Papp; Ildiko Foldi; Istvan Altorjay; Eszter Palyu; Miklos Udvardy; Judit Tumpek; Sandor Sipka; Ilma Rita Korponay-Szabo; Eva Nemes; Gabor Veres; Tamas Dinya; Attila Tordai; Hajnalka Andrikovics; Gary L Norman; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2009-08-21       Impact factor: 5.742

10.  Small intestinal bacterial overgrowth mimicking acute flare as a pitfall in patients with Crohn's Disease.

Authors:  Jochen Klaus; Ulrike Spaniol; Guido Adler; Richard A Mason; Max Reinshagen; Christian von Tirpitz C
Journal:  BMC Gastroenterol       Date:  2009-07-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.